GT300 / Generian - LARVOL DELTA

Grit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting (PRNewswire) - "Grit Biotechnology Co., Ltd...announced today that three abstracts featuring new clinical data from tumor-infiltrating lymphocytes (TIL) therapies will be presented at the American Society of Clinical Oncology (ASCO) 42nd annual meeting, which is taking place in Chicago, IL from May 30th to June 3rd....Grit Bio will provide the clinical updates of its leading TIL programs, including GT101 - an unmodified TIL therapy in treating recurrent and metastatic cervical cancer, GT201 - an armored TIL product expressing membrane bond IL-15 complex in treating various solid tumors, and GT300 - a CRISPR/Cas-edited dual KO TIL product in treating advanced solid tumors."

Clinical data • Cervical Cancer • Solid Tumor

A Phase I Study of GT300 in Healthy Subjects (clinicaltrials.gov) - P1; N=56; Not yet recruiting; Sponsor: Generian Pharmaceuticals, Inc.

Clinical • New P1 trial • Lewy Body Disease